Latanoprost Al

Latanoprost, the active ingredient in Latanoprost Al, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. It treats open-angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Secondary open‑angle glaucoma: assists in pressure reduction when caused by other ocular disorders.

Adverse reactions may occur with ocular prostaglandin therapy.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash changes: increased length, thickness, or darkness. - Iris pigmentation: gradual darkening of the iris. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting clarity. - Increased intra‑ocular pressure: paradoxical pressure rise. - Ocular infection: risk of bacterial or fungal infection. - Vision loss: rare but possible if complications arise.

Patients should be aware of specific safety considerations before using Latanoprost. - Monitor intra‑ocular pressure: schedule regular eye examinations. - Avoid use with active ocular infection: postpone treatment until resolved. - Caution in history of uveitis: assess risk before initiation. - Do not combine with other prostaglandin analogs without supervision: may cause excessive pressure lowering. - Pregnancy and lactation: consult a physician before use. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogs: risk of additive pressure‑lowering effect. - Use with non‑steroidal anti‑inflammatory eye drops: may diminish therapeutic efficacy. - Combination with systemic beta‑blockers: potential for enhanced hypotensive effects.

Moderate Interactions (Monitor Closely): - Co‑administration with topical corticosteroids: may reduce drug absorption. - Use with ocular anesthetics: monitor for increased irritation. - Interaction with antihistamine eye drops: observe for altered intra‑ocular pressure response.